C12Y204/02031

Use of pertussis toxin as a therapeutic agent
11833191 · 2023-12-05 · ·

The present application relates to the use of pertussis toxin, and its derivatives, analogs, salts and pharmaceutical equivalents. In one embodiment, the invention provides a method of treating or preventing a neurological disease or injury by administering pertussis toxin to the individual.

USE OF PERTUSSIS TOXIN AS A THERAPEUTIC AGENT
20210069302 · 2021-03-11 · ·

The present application relates to the use of pertussis toxin, and its derivatives, analogs, salts and pharmaceutical equivalents. In one embodiment, the invention provides a method of treating or preventing a neurological disease or injury by administering pertussis toxin to the individual.

Use of pertussis toxin as a therapeutic agent
10849961 · 2020-12-01 · ·

The present application relates to the use of pertussis toxin, and its derivatives, analogs, salts and pharmaceutical equivalents. In one embodiment, the invention provides a method of treating or preventing a neurological disease or injury by administering pertussis toxin to the individual.

USE OF PERTUSSIS TOXIN AS A THERAPEUTIC AGENT
20200155653 · 2020-05-21 · ·

The present application relates to the use of pertussis toxin, and its derivatives, analogs, salts and pharmaceutical equivalents. In one embodiment, the invention provides a method of treating or preventing a neurological disease or injury by administering pertussis toxin to the individual.

Use of pertussis toxin as a therapeutic agent
10596233 · 2020-03-24 · ·

The present application relates to the use of pertussis toxin, and its derivatives, analogs, salts and pharmaceutical equivalents. In one embodiment, the invention provides a method of treating or preventing a neurological disease or injury by administering pertussis toxin to the individual.

USE OF PERTUSSIS TOXIN AS A THERAPEUTIC AGENT
20240131119 · 2024-04-25 ·

The present application relates to the use of pertussis toxin, and its derivatives, analogs, salts and pharmaceutical equivalents. In one embodiment, the invention provides a method of treating or preventing a neurological disease or injury by administering pertussis toxin to the individual.

USE OF PERTUSSIS TOXIN AS A THERAPEUTIC AGENT
20240226244 · 2024-07-11 ·

The present application relates to the use of pertussis toxin, and its derivatives, analogs, salts and pharmaceutical equivalents. In one embodiment, the invention provides a method of treating or preventing a neurological disease or injury by administering pertussis toxin to the individual.

USE OF PERTUSSIS TOXIN AS A THERAPEUTIC AGENT
20180028623 · 2018-02-01 · ·

The present application relates to the use of pertussis toxin, and its derivatives, analogs, salts and pharmaceutical equivalents. In one embodiment, the invention provides a method of treating or preventing a neurological disease or injury by administering pertussis toxin to the individual.

Use of pertussis toxin as a therapeutic agent
12201678 · 2025-01-21 · ·

The present application relates to the use of pertussis toxin, and its derivatives, analogs, salts and pharmaceutical equivalents. In one embodiment, the invention provides a method of treating or preventing a neurological disease or injury by administering pertussis toxin to the individual.

FURIN-CLEAVABLE DELIVERY CONSTRUCTS
20250099599 · 2025-03-27 ·

The present disclosure provides furin-cleavable delivery constructs that include a transcytosing element that is derived from a mono-ADP-ribosyl transferase and a heterologous cargo that is coupled to the carrier. The carrier is capable of facilitating transport of the heterologous cargo across an epithelial cell via transcytosis. The heterologous cargo may be released from a remaining portion of the delivery construct upon cleavage by a furin protease. The constructs may be used to facilitate delivery of a cargo to a basolateral side of an epithelial membrane.